Principles of mucin architecture: structural studies on synthetic glycopeptides bearing clustered mono-, di-, tri-, and hexasaccharide glycodomains
about
Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs)A Single N-Acetylgalactosamine Residue at Threonine 106 Modifies the Dynamics and Structure of Interferon 2a around the Glycosylation SiteDeciphering Structural Elements of Mucin Glycoprotein RecognitionCell signaling, post-translational protein modifications and NMR spectroscopyPrediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sitesPerturbation of long-range water dynamics as the mechanism for the antifreeze activity of antifreeze glycoprotein.Reconciling solvent effects on rotamer populations in carbohydrates - A joint MD and NMR analysis.Differential analysis of site-specific glycans on plasma and cellular fibronectins: application of a hydrophilic affinity method for glycopeptide enrichment.Influence of solvent and intramolecular hydrogen bonding on the conformational properties of o-linked glycopeptidesOn the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.Polysialic acid and mucin type o-glycans on the neural cell adhesion molecule differentially regulate myoblast fusion.Conformational changes associated with post-translational modifications of Pro(143) in Skp1 of Dictyostelium--a dipeptide model system.TIP5P-Consistent Treatment of Electrostatics for Biomolecular SimulationsPodoplanin requires sialylated O-glycans for stable expression on lymphatic endothelial cells and for interaction with platelets.Synthetic, structural, and biosynthetic studies of an unusual phospho-glycopeptide derived from α-dystroglycan.Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.Chemically tunable mucin chimeras assembled on living cells.Enhanced epimerization of glycosylated amino acids during solid-phase peptide synthesis.Glycosylation of α-dystroglycan: O-mannosylation influences the subsequent addition of GalNAc by UDP-GalNAc polypeptide N-acetylgalactosaminyltransferases.Carbohydrate vaccines as immunotherapy for cancer.Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.Conformational determinants of the activity of antiproliferative factor glycopeptide.Dissecting the molecular basis of the role of the O-mannosylation pathway in disease: α-dystroglycan and forms of muscular dystrophy.Adaptive immune activation: glycosylation does matter.Mucin-type glycopeptide structure in solution: past, present, and future.Critical functions of N-glycans in L-selectin-mediated lymphocyte homing and recruitment.Iron oxide superparamagnetic nanoparticles conjugated with a conformationally blocked α-Tn antigen mimetic for macrophage activation.A Synthetic MUC1 Glycopeptide Bearing βGalNAc-Thr as a Tn Antigen Isomer Induces the Production of Antibodies against Tumor Cells.Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells.Targeted antigen delivery by an anti-class II MHC VHH elicits focused αMUC1(Tn) immunity.Glycosylated analogs of formaecin I and drosocin exhibit differential pattern of antibacterial activity.Initiation of mucin-type O-glycosylation in dictyostelium is homologous to the corresponding step in animals and is important for spore coat function.The nature and sequence of the amino acid aglycone strongly modulates the conformation and dynamics effects of Tn antigen's clusters.Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.Principles of mucin structure: implications for the rational design of cancer vaccines derived from MUC1-glycopeptides.Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate.N-carboxyanhydride polymerization of glycopolypeptides that activate antigen presenting cells through Dectin-1 and -2.Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.The O-linked glycans of human von Willebrand factor modulate its interaction with ADAMTS-13.Engineering O-Glycosylation Points in Non-extended Peptides: Implications for the Molecular Recognition of Short Tumor-Associated Glycopeptides
P2860
Q26823798-12FB9889-DC94-4F37-B4CA-778F3D091521Q27675256-A566BE98-2237-46C1-B1F1-947800D6F8C9Q27678183-6229FF0B-AE2E-4C0B-A642-98EA22920F66Q28830783-DA441182-8126-456F-8F3C-D5042FDB74BAQ29615170-131B349E-090B-4D1F-BF5C-4E2F52C3A19AQ30843588-C562B95E-218D-4FA6-B682-599086A68985Q30882071-3BA442D4-6B78-4130-9642-04168DA7D218Q33220112-8A261F40-B270-4959-BD92-8C6DF5CE6312Q33985110-48EA3E8D-D1BE-4FF5-ADC7-92985B59038BQ34160588-8A812A08-4560-46D0-9364-742471E59D82Q34246992-968A86C4-9081-4CCE-9040-99CD9FA46581Q34489425-CCA035A7-87AD-4323-B770-D132C21C494DQ34554643-FE58A8B9-2EB2-409B-95C0-06A39AFBD689Q34636909-8BC47367-183A-437F-9E03-04D77961934DQ35222634-532AF2CD-EB64-42FC-9466-DF3069980FC2Q35657628-CB1D859A-8819-4B8E-A1D6-0CD683CC5312Q35792966-4E33E44D-69C2-43C3-8342-6F6F339082A3Q35884182-9A86A4C5-69D2-4C42-846E-F1A4084D56F6Q36033160-7D82E896-8073-4DB3-8479-6676C38E80E3Q36201691-15770BFD-F194-4251-BCF1-23EDB1DBA51CQ36221411-52840163-3BA1-424F-A2A5-3732F6E48B1FQ36948082-413CCB47-1B7F-4915-B6B2-5CAC9D13271BQ37609175-FBF9DAC1-7000-48AC-8816-870E9EFB05FFQ37663706-9523C506-C693-49F3-B170-DE6268CB0F7BQ38114359-5AD66F08-BDDD-4FCF-B69E-B32CC0B09CEAQ38304128-0685A21C-3EA7-453B-AC78-A723D033FBBDQ38988340-EFB83042-6EA5-4C23-8D8E-ECEE91ABE2C5Q39031519-FB351185-C2ED-4FA4-BF3F-D3B3599635A7Q41568866-46178209-4338-45CB-A7F0-13BCFAC82AFEQ41828763-A169B3E9-6101-4D73-946D-27A1C2D6BF08Q44063337-BD77C1F6-7069-4818-9564-F75ECC357F9AQ44613042-C9307A5C-F527-4C29-845F-6FA3965F64BDQ46116013-3E7A74CC-46FA-4125-8669-087BA52E9AE3Q47626278-27A75248-4760-4B31-9080-80DB2D6E1BEDQ47902181-BAB2448D-2860-470E-898E-0DB905366310Q48246161-2B3E27DA-93D0-4B58-ADEB-5919254CA8CAQ49690970-0C8B5FEF-75DF-41A5-BD49-2FC65CD086ECQ50908486-2DEFF136-FEC4-4BD4-AE31-639EA682B32DQ53073825-79462D94-90B7-4AB4-BEB8-E9F34C7F3C93Q57515385-0C5A437A-9A1B-41EA-8D9E-1519A5832900
P2860
Principles of mucin architecture: structural studies on synthetic glycopeptides bearing clustered mono-, di-, tri-, and hexasaccharide glycodomains
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Principles of mucin architectu ...... nd hexasaccharide glycodomains
@ast
Principles of mucin architectu ...... nd hexasaccharide glycodomains
@en
Principles of mucin architectu ...... nd hexasaccharide glycodomains
@nl
type
label
Principles of mucin architectu ...... nd hexasaccharide glycodomains
@ast
Principles of mucin architectu ...... nd hexasaccharide glycodomains
@en
Principles of mucin architectu ...... nd hexasaccharide glycodomains
@nl
prefLabel
Principles of mucin architectu ...... nd hexasaccharide glycodomains
@ast
Principles of mucin architectu ...... nd hexasaccharide glycodomains
@en
Principles of mucin architectu ...... nd hexasaccharide glycodomains
@nl
P2093
P356
P1476
Principles of mucin architectu ...... nd hexasaccharide glycodomains
@en
P2093
Ajay K Royyuru
Dalibor Sames
David H Live
Don M Coltart
Jacob B Schwarz
Lawrence J Williams
Peter W Glunz
Samuel J Danishefsky
Scott D Kuduk
Xiao-Tao Chen
P304
P356
10.1021/JA020208F
P407
P577
2002-08-21T00:00:00Z